(Q37969899)

26 August 2017

title

Tumor control versus adverse events with targeted anticancer therapies (English)

1 reference

26 August 2017

Dorothy M K Keefe

1

1 reference

26 August 2017

Emma H Bateman

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

20 December 2011

1 reference

Nature Reviews Clinical Oncology

26 August 2017

published in

1 reference

26 August 2017

volume

9

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

98-109

1 reference

DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Value and cancer care: toward an equitable future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Toxicities of targeted therapy and their management in kidney cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Crizotinib: an anaplastic lymphoma kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Targeting anaplastic lymphoma kinase in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Trastuzumab: A review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

ASCO Provisional Clinical Opinion: KRAS, Cetuximab, and Panitumumab—Clinical Implications in Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Cardiac toxicity from systemic cancer therapy: a comprehensive review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Added value of molecular targeted agents in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Development of targeted therapy for squamous cell carcinomas of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Crizotinib in anaplastic large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Early accelerated approval for highly targeted cancer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

RETRACTED: A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

The concept of synthetic lethality in the context of anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

mTOR inhibitors in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Tailoring tyrosine kinase inhibitors to fit the lung cancer genome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

The GIST paradigm: lessons for other kinase-driven cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Genomic signatures for individualized treatment of malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Advances in understanding of toxicities of treatment for head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Review: side effects of approved molecular targeted therapies in solid cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Analysis of dermatologic events in patients with cancer treated with lapatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

VEGF kinase inhibitors: how do they cause hypertension?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Management of hypertension in angiogenesis inhibitor-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Intricacies of bevacizumab-induced toxicities and their management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Incidence and management of bevacizumab-related toxicities in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Cardiotoxicity of anticancer treatments: what the cardiologist needs to know

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Pooled analysis of diarrhea events in patients with cancer treated with lapatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Mucosal injury from targeted anti-cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Efficacy and safety of deep, continuous palliative sedation at home: a retrospective, single-institution study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

HER2 targeted therapies for cancer and the gastrointestinal tract.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Molecular and clinical aspects of targeting the VEGF pathway in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Clinical pharmacokinetics of tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Rationale for treatment durations of targeted cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Use of molecular markers for predicting therapy response in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

American Society of Clinical Oncology guidance statement: the cost of cancer care

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Electronic patient-reported data capture as a foundation of rapid learning cancer care

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Cancer survivorship and employment: epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Work in cancer survivors: a model for practice and research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Personalized medicine in oncology: a personal view with myths and facts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Skin toxicity of anti-cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Hypertension as a surrogate marker for the activity of anti-VEGF agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

OncomiRs: the discovery and progress of microRNAs in cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Silencing human cancer: identification and uses of microRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Personalized medicine in oncology: the future is now.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Maximum tolerated dose: clinical endpoint for a bygone era?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Selective antagonism of anticancer drugs for side-effect removal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Women survive breast cancer but fall victim to heart failure: the shadows and lights of targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Retrospective analysis of cetuximab monotherapy for patients with irinotecan-intolerant metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Toxicity of targeted therapy in non-small-cell lung cancer management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Vandetanib for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin's lymphoma in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Practical management of tyrosine kinase inhibitor-associated side effects in GIST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Handling side-effects of targeted therapies: safety of targeted therapies in solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Gene expression of insulin-like growth factors and receptors in neoplastic prostate tissues: correlation with clinico-pathological parameters

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver - Will it hit the moving target?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Cancer survivors' and employers' perceptions of working following cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Dose selection in phase I studies: why we should always go for the top

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Efficacy and toxicity of erlotinib in non-small cell lung cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.192

Ipilimumab approved for metastatic melanoma

31 March 2020

1 reference

12 December 2020

Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer

1 reference

12 December 2020

Integration of novel agents in the treatment of colorectal cancer

1 reference

12 December 2020

Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia

1 reference

12 December 2020

Cardiac toxicity in cancer therapy

1 reference

12 December 2020

Cutaneous reactions to epidermal growth factor receptor inhibitors.

1 reference

12 December 2020

A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System

1 reference

12 December 2020

Erlotinib in the treatment of non-small cell lung cancer: current status and future developments.

1 reference

12 December 2020

Alemtuzumab: what is the secret to safe therapy?

1 reference

12 December 2020

[Epidermal growth factor receptor mutation in Chinese patients with non-small cell lung cancer]

1 reference

12 December 2020

Ileal perforation induced by acute radiation injury under gefitinib treatment.

1 reference

12 December 2020

Targeted therapies: a new generation of cancer treatments.

1 reference

12 December 2020

Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors--the first molecular targeted treatment

1 reference

12 December 2020

Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines

1 reference

12 December 2020

10.1038/NRCLINONC.2011.192

Identifiers

DOI

1 reference

26 August 2017

1 reference